BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer

PARP inhibition is known to be an effective clinical strategy in BRCA-mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here we show synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Rep
Auteurs principaux: Karakashev, Sergey, Zhu, Hengrui, Yokoyama, Yuhki, Zhao, Bo, Fatkhutdinov, Nail, Kossenkov, Andrew V., Wilson, Andrew J., Simpkins, Fiona, Speicher, David, Khabele, Dineo, Bitler, Benjamin G., Zhang, Rugang
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5745042/
https://ncbi.nlm.nih.gov/pubmed/29262321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.11.095
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires